Silhouette

Anne Searls Degroot

Epivax, Inc.

Employers

Affiliated Awards

Award Title Agency Phase Award amount Start Date End Date
Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis ...
Epivax, Inc.
Principal Investigator
HHS 1 $177K 09/01/17 08/31/18
Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza
Epivax, Inc.
Principal Investigator
HHS 1 $291K 07/01/17 06/30/18
Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza
Epivax, Inc.
Principal Investigator
HHS 1 $300K 07/01/16 06/30/17
Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease
Epivax, Inc.
Principal Investigator
HHS 1 $300K 09/01/13 08/31/14
Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A
Epivax, Inc.
Principal Investigator
HHS 1 $376K 07/01/13 06/30/14
EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of
Epivax, Inc.
Principal Investigator
HHS 2 $728K 04/01/13 03/31/14
Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease
Epivax, Inc.
Principal Investigator
HHS 1 $300K 09/01/12 08/31/13
Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A
Epivax, Inc.
Principal Investigator
HHS 1 $381K 07/15/12 06/30/13
Preclinical Studies of Tregitope Delivery and Mechanism of Action in T1D
Epivax, Inc.
Principal Investigator
HHS 2 $747K 04/01/12 03/31/13
Epitope-driven deimmunization of Factor VIII
Epivax, Inc.
Principal Investigator
HHS 1 $174K 09/10/10 06/30/11
T1D Tolerance Induction with Natural Treg Epitopes
Epivax, Inc.
Principal Investigator
HHS 1 $106K 07/01/09 06/30/11